Maze Therapeutics said on Thursday that it raised $140 million in an initial public offering, setting the stage for a debut that could make the kidney disease drug developer the first U.S. biotech ...

A pair of drugmakers priced their initial public offerings on Thursday, delivering the best month for US health care ...

The offerings reflect an increase in IPO activity that could continue, as four other biotechs recently outlined plans to go ...

Maze Therapeutics, Inc MAZE IPO will take place January, 31 on the NASDAQ exchange under the ticker MAZE. The company is offering shares at an expected price between $15.00 and $17.00 per share with ...

Beta Bionics has begun life as a public company with a $204m initial public offering (IPO), significantly higher than its anticipated target. The US-based company sold 12 million shares of its common ...

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, ...

Teoxane, which holds a 6.2% stake in Revance and is a key customer of the Nashville, Tenn., company, had proposed buying the rest of the company for $3.60 a share after Crown reduced its planned ...

With the Fed's two-day FOMC meeting concluding yesterday, no offerings were priced in the IG primary, leaving weekly IG issuance so far to date at US$11.67bn, according to IFR data. But that will ...

Merck & Co. Inc. 0.85% $248.61B ...